Statement of Policy Intent sets out initial thinking on a new Early Access service to help patients benefit sooner from innovative medical devices that address unmet clinical needs.
Similar Posts
MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy
Guidance: AI Airlock Phase 2 Cohort
Phase 2 of the Airlock will include seven additional technologies spanning AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems.
Decision: Advertising Investigations: January 2026
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Decentralised Manufacture: Labelling
Guidance on labelling requirements pertinent to the type of medicinal product and its supply status, as defined in UK legislation.
Contact the MHRA
How to contact the MHRA for specific services or enquiries.
Guidance: Centres of Excellence for Regulatory Science and Innovation (CERSIs)
An initiative to help drive advancements in healthcare, to ensure patients benefit from innovation and new treatments sooner.